Literature DB >> 17568824

Management of chronic hepatitis C: consensus guidelines.

Morris Sherman1, Stephen Shafran, Kelly Burak, Karen Doucette, Winnie Wong, Nigel Girgrah, Eric Yoshida, Eberhard Renner, Philip Wong, Marc Deschênes.   

Abstract

Since the last consensus conference on the management of chronic viral hepatitis, a number of studies looking at modifications of the standard course of treatment have been published. These changes have been sufficiently substantive to warrant review to determine whether any changes in the recommended treatment algorithms are needed. A consensus development conference was held in January 2007, and the present document highlights the results of the presentations and discussion about these issues. It reviews the epidemiology of hepatitis C in Canada, treatment of acute hepatitis C and new algorithms in chronic hepatitis C, including retreatment of previous treatment failures. In addition, sections on management of hepatitis C in special populations have been updated. There is also a section on the use of hematopoietic growth factors to help manage patients on therapy. The document should be read in conjunction with the previous document to identify changes. Some recommendations made in the previous document remain and are not discussed here.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568824      PMCID: PMC2794457     

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  88 in total

1.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Authors:  Montserrat Laguno; Javier Murillas; José Luis Blanco; Esteban Martínez; Rosa Miquel; José M Sánchez-Tapias; Xavier Bargallo; Angeles García-Criado; Elisa de Lazzari; María Larrousse; Agathe León; Montserrat Loncá; Ana Milinkovic; Josep M Gatell; Josep Mallolas
Journal:  AIDS       Date:  2004-09-03       Impact factor: 4.177

2.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

3.  HIV and hepatitis C coinfection within the CAESAR study.

Authors:  J Amin; M Kaye; S Skidmore; D Pillay; D A Cooper; G J Dore
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

4.  A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.

Authors:  Stefan Mauss; Florian Berger; Joerg Goelz; Bernhard Jacob; Günther Schmutz
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

5.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

6.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

7.  Peg-Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results.

Authors:  Ioan Sporea; Roxana Sirli; Ovidiu Golea; Camelia Totolici; Mirela Danila; Alina Popescu
Journal:  Rom J Gastroenterol       Date:  2004-06

Review 8.  Treatment of chronic hepatitis C in patients with decompensated cirrhosis.

Authors:  Gregory T Everson
Journal:  Rev Gastroenterol Disord       Date:  2004

9.  Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study.

Authors:  Eric A Engels; Nilanjan Chatterjee; James R Cerhan; Scott Davis; Wendy Cozen; Richard K Severson; Denise Whitby; Joanne S Colt; Patricia Hartge
Journal:  Int J Cancer       Date:  2004-08-10       Impact factor: 7.396

10.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

View more
  50 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.

Authors:  Angelique Myles; Gerry J Mugford; Jing Zhao; Murray Krahn; Peizhong P Wang
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

4.  Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia.

Authors:  Rohit Pai; Alnoor Ramji; Samuel S Lee; Winnie W Wong; Eric M Yoshida
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08

5.  Optimizing hepatitis C therapy in HIV/hepatitis C virus (HCV) coinfected patients: Analysis of HCV viral kinetics on treatment.

Authors:  Paul Damien James; David Kh Wong
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

6.  Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients.

Authors:  Fazal A Danish; Salman S Koul; Fazal R Subhani; Ahemd E Rabbani; Saeeda Yasmin
Journal:  Saudi J Gastroenterol       Date:  2008-07       Impact factor: 2.485

7.  HCV co-infection in HIV positive population in British Columbia, Canada.

Authors:  Jane A Buxton; Amanda Yu; Paul H Kim; John J Spinelli; Margot Kuo; Maria Alvarez; Mark Gilbert; Mel Krajden
Journal:  BMC Public Health       Date:  2010-04-29       Impact factor: 3.295

Review 8.  Hepatitis C treatment: current and future perspectives.

Authors:  Saira Munir; Sana Saleem; Muhammad Idrees; Aaliyah Tariq; Sadia Butt; Bisma Rauff; Abrar Hussain; Sadaf Badar; Mahrukh Naudhani; Zareen Fatima; Muhmmad Ali; Liaqat Ali; Madiha Akram; Mahwish Aftab; Bushra Khubaib; Zunaira Awan
Journal:  Virol J       Date:  2010-11-01       Impact factor: 4.099

9.  Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients.

Authors:  Hana A Elasifer; Yossif M Agnnyia; Basher A Al-Alagi; Mohamed A Daw
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

Review 10.  Antiviral therapy in HCV-infected decompensated cirrhotics.

Authors:  Fazal A Danish; Salman S Koul; Fazal R Subhani; Ahmed E Rabbani; Saeeda Yasmin
Journal:  Saudi J Gastroenterol       Date:  2010 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.